Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
789 studies found for:    anti-EGFR monoclonal antibodies
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
2 Completed Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
Condition: Recurrent Head and Neck Cancer
Intervention: Drug: IPI-926 and Cetuximab
3 Completed Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Cetuximab
4 Terminated An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Condition: Carcinoma, Squamous Cell
Intervention: Drug: Cetuximab
5 Terminated An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
6 Completed Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Cetuximab
7 Recruiting Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Dose escalation cetuximab;   Drug: Standard dose cetuximab
8 Completed
Has Results
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Cetuximab + concomitant boost radiotherapy
9 Active, not recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
10 Terminated EMMA-1 (Erbitux for Multiple Myeloma)
Condition: Multiple Myeloma
Intervention: Drug: Cetuximab +/- Dexamethasone
11 Recruiting Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Condition: Head and Neck Cancer
Intervention: Drug: Cetuximab-IRDye800
12 Recruiting Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: Copanlisib;   Drug: Cetuximab
13 Active, not recruiting Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head And Neck
Interventions: Drug: Ficlatuzumab;   Drug: Cetuximab
14 Recruiting Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Cetuximab
15 Completed
Has Results
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Conditions: Head and Neck;   Squamous Cell Cancer
Intervention: Biological: cetuximab
16 Completed Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
Conditions: Skin Diseases;   Carcinoma, Squamous Cell
Intervention: Drug: cetuximab
17 Active, not recruiting Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab
Condition: Colorectal Cancer Metastatic
Intervention: Drug: Cetuximab
18 Active, not recruiting A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
Conditions: Oropharyngeal Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer
Intervention: Drug: Cetuximab
19 Completed Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: Cetuximab
20 Completed FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer
Condition: Esophageal Cancer Stage III
Intervention: Drug: radiochemotherapy,combination Cetuximab-FOLFOX

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.